In contrast, no substantial differences in survival outcomes are observed between high and low sPD-1 groups, suggesting limited prognostic value for this marker, except in the case of bone tumors, where patients with lower sPD-1 levels showed slightly improved prognosis. The gene discussed is HOXD13; the disease is bone neoplasm.